Departments of Radiology, Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Ultrasound Med Biol. 2013 Nov;39(11):2137-46. doi: 10.1016/j.ultrasmedbio.2013.05.007. Epub 2013 Aug 9.
In contrast to the clinically used microbubble ultrasound contrast agents, nanoscale bubbles (or nanobubbles) may potentially extravasate into tumors that exhibit more permeable vasculature, facilitating targeted molecular imaging and drug delivery. Our group recently presented a simple strategy using the non-ionic surfactant Pluronic as a size control excipient to produce nanobubbles with a mean diameter of 200 nm that exhibited stability and echogenicity on par with microbubbles. The objective of this study was to carry out an in-depth characterization of nanobubble properties as compared with Definity microbubbles, both in vitro and in vivo. Through use of a tissue-mimicking phantom, in vitro experiments measured the echogenicity of the contrast agent solutions and the contrast agent dissolution rate over time. Nanobubbles were found to be more echogenic than Definity microbubbles at three different harmonic frequencies (8, 6.2 and 3.5 MHz). Definity microbubbles also dissolved 1.67 times faster than nanobubbles. Pharmacokinetic studies were then performed in vivo in a subcutaneous human colorectal adenocarcinoma (LS174T) in mice. The peak enhancement and decay rates of contrast agents after bolus injection in the liver, kidney and tumor were analyzed. No significant differences were observed in peak enhancement between the nanobubble and Definity groups in the three tested regions (tumor, liver and kidney). However, the decay rates of nanobubbles in tumor and kidney were significantly slower than those of Definity in the first 200-s fast initial phase. There were no significant differences in the decay rates in the liver in the initial phase or in three regions of interest in the terminal phase. Our results suggest that the stability and acoustic properties of the new nanobubble contrast agents are superior to those of the clinically used Definity microbubbles. The slower washout of nanobubbles in tumors suggests potential entrapment of the bubbles within the tumor parenchyma.
与临床使用的微泡超声造影剂相反,纳米气泡(或纳米微泡)可能会渗漏到具有更通透性血管的肿瘤中,从而促进靶向分子成像和药物输送。我们的小组最近提出了一种简单的策略,使用非离子表面活性剂泊洛沙姆作为尺寸控制赋形剂,产生平均直径为 200nm 的纳米微泡,其稳定性和超声回声与微泡相当。本研究的目的是深入比较纳米微泡和 Definity 微泡的性质,包括在体和体外。通过使用组织模拟体模,体外实验测量了对比剂溶液的超声回声和对比剂随时间的溶解速率。在三个不同的谐波频率(8、6.2 和 3.5MHz)下,纳米微泡比 Definity 微泡更具超声回声。Definity 微泡的溶解速度也比纳米微泡快 1.67 倍。然后在小鼠皮下人结直肠腺癌(LS174T)中进行了体内药代动力学研究。分析了肝脏、肾脏和肿瘤中对比剂在推注后的峰值增强和衰减率。在三个测试区域(肿瘤、肝脏和肾脏)中,纳米微泡和 Definity 组的峰值增强没有显著差异。然而,在快速初始阶段的前 200 秒内,纳米微泡在肿瘤和肾脏中的衰减率明显慢于 Definity 的衰减率。在初始阶段的肝脏或三个感兴趣区域的终末阶段,衰减率没有显著差异。我们的结果表明,新型纳米微泡造影剂的稳定性和声学特性优于临床使用的 Definity 微泡。纳米微泡在肿瘤中的洗脱速度较慢表明气泡可能被困在肿瘤实质中。